Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) Gallery Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) 美国投资项目 Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) 2022-03-09 14:23:29 03月 09日, 2022 | 阅读更多
Vivo Capital, Co-Leads a $75m Series A Round of Financing in Ablaze Pharmaceuticals Gallery Vivo Capital, Co-Leads a $75m Series A Round of Financing in Ablaze Pharmaceuticals 美国投资项目 Vivo Capital, Co-Leads a $75m Series A Round of Financing in Ablaze Pharmaceuticals 2022-03-09 14:22:32 03月 09日, 2022 | 阅读更多
Vivo Capital, Leads a $200m Series A Round of Financing in Avistone Pharmaceuticals Gallery Vivo Capital, Leads a $200m Series A Round of Financing in Avistone Pharmaceuticals 美国投资项目 Vivo Capital, Leads a $200m Series A Round of Financing in Avistone Pharmaceuticals 2022-03-09 14:21:40 03月 09日, 2022 | 阅读更多
Legend Biotech Announces FDA Approval of CARVYKTI Gallery Legend Biotech Announces FDA Approval of CARVYKTI 美国投资项目 Legend Biotech Announces FDA Approval of CARVYKTI 2022-03-09 09:29:48 03月 09日, 2022 | 阅读更多